Novacyt

Novacyt FCF/Net Income

The Free Cash Flow to Net Income Ratio of Novacyt (ALNOV.PA) as of Oct 18, 2026 is 38.74 %. In the previous year, Free Cash Flow to Net Income Ratio was 24.79 % — a change of 56.30% (higher).

FCF/Net Income

38.74 %

YoY

56.30%

Last updated:

Free Cash Flow to Net Income Ratio of Novacyt is 2025 38.74 % . Free Cash Flow to Net Income Ratio of Novacyt was 2024 24.79 % . It decreases by 56.30% higher compared to the previous year.

The Novacyt FCF/Net Income history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Net Income
Date
FCF/Net Income
Jan 1, 2018
36.72 GBP
Jan 1, 2019
18.37 GBP
Jan 1, 2020
76.87 GBP
Jan 1, 2021
-119.13 GBP
Jan 1, 2022
54.97 GBP
Jan 1, 2023
90.70 GBP
Jan 1, 2024
24.79 GBP
Jan 1, 2025
38.74 GBP
The Novacyt FCF/Net Income history
YEARFCF/Net IncomeYoY
38.74 %+56.30%
24.79 %-72.67%
90.70 %+64.99%
54.97 %-146.15%
-119.13 %-254.97%
76.87 %+318.46%
18.37 %-49.97%
36.72 %-64.47%
103.34 %+89.86%
54.43 %+22.59%
44.40 %+48.91%
29.82 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Novacyt Stock analysis

What does Novacyt do? Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Novacyt stock

Free Cash Flow to Net Income Ratio of Novacyt is 38.74 % in 2025.

Free Cash Flow to Net Income Ratio of Novacyt changed from 24.79 % to 38.74 %, representing a 56.30% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Net Income Ratio Novacyt since 2006 – with annual values, charts, and detailed analysis.

The FCF/Net Income ratio measures cash flow quality. Ratios consistently above 100% suggest high-quality earnings with strong cash backing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Net Income Ratio's Novacyt with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow to Net Income Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow to Net Income Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Novacyt

All Key Metrics — Novacyt